AAAAAA

   
Results: 1-8 |
Results: 8
A feasibility study using polychemotherapy (cisplatin plus vindesine plus dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma
Authors: Bajetta, E Del Vecchio, M Vitali, M Martinetti, A Ferrari, L Queirolo, P Sertoli, MR Cainelli, T Cellerino, R Cascinelli, N
Citation: E. Bajetta et al., A feasibility study using polychemotherapy (cisplatin plus vindesine plus dacarbazine) plus interferon-alpha or monochemotherapy with dacarbazine plus interferon-alpha in metastatic melanoma, TUMORI, 87(4), 2001, pp. 219-222
Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy
Authors: Pronzato, P Queirolo, P Vecchio, S Lionetto, R Del Mastro, L Venturini, M Gardin, G Alama, A Sertoli, MR
Citation: P. Pronzato et al., Thymidine labeling index analysis in early breast cancer patients randomized to receive perioperative chemotherapy, ONCOL-BASEL, 60(1), 2001, pp. 88-93
Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients
Authors: Bertelli, G Queirolo, P Vecchio, S Angiolini, C Bergaglio, M Del Mastro, L Signorini, A Valenzano, M Venturini, M
Citation: G. Bertelli et al., Toremifene as a substitute for adjuvant tamoxifen in breast cancer patients, ANTICANC R, 20(5C), 2000, pp. 3659-3661
Selective lymph node dissection in patients with intermediate thickness melanoma: Our experience
Authors: Cafiero, F Peressini, A Percivale, PL Rainero, ML Faggioni, M Gipponi, M Queirolo, P Nicolo, G Bertoglio, S
Citation: F. Cafiero et al., Selective lymph node dissection in patients with intermediate thickness melanoma: Our experience, ANTICANC R, 20(1B), 2000, pp. 497-500
Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase III pilot trial
Authors: Queirolo, P Ponte, M Gipponi, M Cafiero, F Peressini, A Semino, C Pietra, G Lionetto, R Vecchio, S Ribizzi, I Melioli, G Sertoli, MR
Citation: P. Queirolo et al., Adoptive immunotherapy with tumor-infiltrating lymphocytes and subcutaneous recombinant interleukin-2 plus interferon alfa-2a for melanoma patients with nonresectable distant disease: A phase III pilot trial, ANN SURG O, 6(3), 1999, pp. 272-278
Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience
Authors: Semino, C Martini, L Queirolo, P Cangemi, G Costa, R Alloisio, A Ferlazzo, G Sertoli, MR Reali, UM Ratto, GB Melioli, G
Citation: C. Semino et al., Adoptive immunotherapy of advanced solid tumors: An eight year clinical experience, ANTICANC R, 19(6C), 1999, pp. 5645-5649
Mitoxantrone in elderly patients with advanced breast cancer: Pharmacokinetics, marrow and peripheral hematopoietic progenitor cells
Authors: Repetto, L Vannozzi, MO Balleari, E Venturino, A Granetto, C Bason, C Simoni, C Prencipe, E Queirolo, P Esposito, M Ghio, R Rosso, R
Citation: L. Repetto et al., Mitoxantrone in elderly patients with advanced breast cancer: Pharmacokinetics, marrow and peripheral hematopoietic progenitor cells, ANTICANC R, 19(1B), 1999, pp. 879-884
Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia
Authors: Ghiorzo, P Ciotti, P Mantelli, M Heouaine, A Queirolo, P Rainero, ML Ferrari, C Santi, PL De Marchi, R Farris, A Ajmar, F Bruzzi, P Bianchi-Scarra, G
Citation: P. Ghiorzo et al., Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia, INT J CANC, 83(4), 1999, pp. 441-448
Risultati: 1-8 |